New hope for Hard-to-Treat breast cancer: experimental drug CLR 125 enters human testing
NCT ID NCT07311993
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study is testing an experimental drug called CLR 125 in 60 people with advanced triple-negative breast cancer that has not responded to prior treatments. The main goals are to find the safest and most effective dose and to understand what side effects occur. Participants receive the drug by infusion four times per 8-week cycle and will have regular clinic visits for monitoring.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
Locations
-
Mayo Clinic Florida
RECRUITINGJacksonville, Florida, 32224, United States
-
Mayo Clinic Rochester
RECRUITINGRochester, Minnesota, 55905, United States
-
United Theranostics
RECRUITINGGlen Burnie, Maryland, 21061, United States
Contact Email: •••••@•••••
-
United Theranostics
RECRUITINGPrinceton, New Jersey, 08540, United States
Contact Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a radioactive tracer pinpoint Cancer's first stop?
- Can a personalized exercise program boost recovery in cancer survivors?
- Smartwatch could spot nerve damage before it starts
- Could ionized gas help fight breast cancer after surgery?
- Radiation may let breast cancer patients keep their nipple
- Can a smart digital program restore sleep for cancer survivors?